Artivion (AORT)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$25.57-0.20%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · AORT
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $26 the market pays 47× p/e — above the 28× p/e peer median but in line with its own 46× history. That premium reflects a durable franchise our peer-anchored $24 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts target $36–$45. Note: our $24 fair value sits below the entire analyst range ($36–$45). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $39.50 | — | — | Analyst | high |
| graham number | 12M | $10.56 | — | — | TTM | high |
| Peer P/S | 12M | $28.59 | 2.9 | 9.71 | TTM | high |
| residual income | 12M | $8.38 | — | — | TTM | high |
| Own P/E history |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$36.00 – $45.00 (median $39.50) · 4 analysts · as of 2026-08-18
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $24.67 |
| 45.7 |
| 0.54 |
| TTM |
| high |
| triangulated | 12M | $15.72 | 28.3 | 0.56 | Triangulated | high |
| Peer P/E | 3Y | $5.76 | 18.7 | 0.31 | Analyst | medium |
| Peer P/S | 3Y | $34.99 | 2.9 | 11.89 | guidance | medium |
| Own P/E history | 3Y | $5.97 | 45.7 | 0.13 | Analyst | medium |
| Peer P/E | 5Y | $6.17 | 18.7 | 0.33 | Analyst | medium |
| Peer P/S | 5Y | $37.48 | 2.9 | 12.73 | guidance | medium |